8-K: Altria Reports Solid 2024 Results, Announces New Share Repurchase Program and Provides 2025 Guidance

Altria reported its 2024 fourth-quarter and full-year results, provided 2025 earnings guidance, and announced a new $1 billion share repurchase program.

Summary

• Altria's 2024 was marked by progress towards its vision, strong financial results, and significant cash returns to shareholders.
• The company expects 2025 full-year adjusted diluted EPS to be between $5.22 and $5.37, representing a 2% to 5% growth rate from a 2024 base of $5.12.
• Net revenues for 2024 were $24.018 billion, a decrease of 1.9% compared to 2023.
• Adjusted diluted EPS for 2024 was $5.12, a 3.4% increase compared to 2023.
• A new $1 billion share repurchase program was authorized, expected to be completed by December 31, 2025.
• The company paid dividends of $6.8 billion for the full year 2024.
• NJOY consumables shipment volume increased by 15.3% in the fourth quarter and 46.6 million units for the full year.
• The company is reassessing its 2028 smoke-free volume and revenue goals due to the growth of illicit e-vapor products.
• Helix achieved profitability in the fourth quarter of 2024, ahead of its 2025 goal.
• The company completed an equity and civil rights assessment in 2024.
• The company's 2025 full-year adjusted effective tax rate is expected to be between 23% and 24%.

Sentiment

Score: 7

Explanation: The document presents a mixed picture with positive financial results and shareholder returns, but also acknowledges challenges in the e-vapor market and the need to reassess some goals. The overall tone is cautiously optimistic.

Positives

• Altria achieved a 3.4% increase in adjusted diluted EPS for 2024.
• The company's adjusted OCI margin was 60.3% for 2024, exceeding the target of at least 60%.
• NJOY's shipment volumes for both consumables and devices increased significantly.
• Helix achieved profitability ahead of schedule.
• The company is returning significant cash to shareholders through dividends and share repurchases.
• The company is maintaining its leadership position in the U.S. tobacco space.
• The company is making progress in its international expansion with on! and SWIC products.
• The company is exploring non-nicotine categories with a minority investment in Proper Wild.

Negatives

• Net revenues decreased by 1.9% in 2024.
• The company is reassessing its 2028 smoke-free volume and revenue goals due to the growth of illicit e-vapor products.
• The company's smokeable products segment reported a decrease in domestic cigarette shipment volume of 10.2% for the full year.
• The company's oral tobacco products segment reported a decrease in domestic shipment volume of 1.0% for the full year.
• Marlboro's retail share of the total cigarette category decreased by 0.5 share points versus the prior year.
• The company's oral tobacco products segment retail share decreased by 5.0 share points versus the prior year.
• The company's 2025 full-year adjusted diluted EPS guidance includes the impact of one fewer shipping day in the first quarter.

Risks

• The growth of illicit e-vapor products is impacting the company's ability to achieve its smoke-free goals.
• The company faces challenges in the e-vapor market due to the proliferation of illicit disposable products.
• The company is subject to regulatory and litigation risks, including the ITC's decision against NJOY.
• The company's performance is affected by changes in adult tobacco consumer preferences and purchasing behavior.
• The company is exposed to risks related to macroeconomic conditions, including inflation.
• The company's ability to achieve its goals is dependent on its ability to develop and commercialize innovative products.
• The company is subject to risks related to its international business operations.
• The company is subject to risks related to climate change and other environmental sustainability matters.
• The company is subject to risks related to cyber-attacks and security breaches.

Future Outlook

Altria expects to deliver 2025 full-year adjusted diluted EPS in a range of $5.22 to $5.37, representing a growth rate of 2% to 5% from a base of $5.12 in 2024. The company will continue to monitor conditions related to the economy, adult tobacco consumer dynamics, illicit product enforcement, and regulatory, litigation, and legislative developments.

Management Comments

• 2024 was another pivotal year for Altria, headlined by meaningful progress toward our Vision, strong financial results and significant cash returns to shareholders, said Billy Gifford, Altrias Chief Executive Officer.
• Our companies leading brands and talented teams enabled our core tobacco businesses to deliver solid income growth and margin expansion, while we strategically invested in our future.

Industry Context

The report highlights the challenges Altria faces due to the growth of illicit e-vapor products, which is impacting the entire legitimate e-vapor market. The company is also navigating a changing landscape with the growth of oral nicotine pouches and the decline in traditional cigarette consumption. The company is also investing in smoke-free products and exploring non-nicotine categories to diversify its portfolio.

Comparison to Industry Standards

• Altria's performance is being impacted by the same trends affecting other tobacco companies, including the decline in cigarette consumption and the rise of alternative nicotine products.
• The company's focus on smoke-free products aligns with the industry's shift towards potentially less harmful alternatives.
• The company's share repurchase program is a common practice among large, established companies to return value to shareholders.
• The company's adjusted OCI margin of 60.3% is a key metric that is closely watched by investors and is comparable to other large tobacco companies.
• The company's challenges with illicit e-vapor products are also being faced by other companies in the industry, such as British American Tobacco and Imperial Brands.

Management Changes

Legal Proceedings

• The ITC issued a final determination in JUUL Labs, Inc.'s case against NJOY, agreeing with JUUL's claims with respect to four patents. The ITC issued an exclusion order and cease-and-desist orders barring the importation and sale of ACE. The ITCs decision is currently under a 60-day review period by the Office of the U.S. Trade Representative, which could reject the ITCs decision.

Stakeholder Impact

• Shareholders will benefit from the share repurchase program and dividend payments.
• Employees may be affected by the company's cost-saving initiatives.
• Customers will see continued investment in smoke-free products and new product categories.
• Suppliers may be impacted by changes in the company's supply chain.
• Creditors will be interested in the company's debt-to-EBITDA ratio and its ability to meet its obligations.

Next Steps

• The company will continue to monitor market conditions and adjust its strategies as needed.
• The company will complete the new $1 billion share repurchase program by December 31, 2025.
• The company will continue to invest in its smoke-free portfolio and explore non-nicotine categories.
• The company will provide updated smoke-free goals when it has more clarity on how the legitimate e-vapor market may evolve.

Key Dates

Keywords

Altria, Tobacco, E-vapor, Smoke-free, Share Repurchase, Dividends, Earnings, NJOY, Oral Tobacco, Cigarettes, Financial Results, Guidance